MCTC Holdings Inc. (MCTC) Files Fifth Patent on Heels of Positive Lab Results for Revolutionary CBD Technology

  • MCTC Holdings Inc. is engaged in developing infusion technologies, including nanoparticles, for making hemp extracts more bioavailable to users through the bloodstream
  • The company has a particular goal of promoting beverage infusion superior to anything existing in the industry as a potential replacement for alcohol and alcohol’s negative health effects
  • MCTC has filed its fifth patent under its Hemp You Can Feel brand after lab results exceeded the company’s expectations for demonstrating cannabis particle infusion on a minuscule, undetectable basis

Cannabinoid science innovator MCTC Holdings Inc. (OTC: MCTC), a Delaware-registered, fully reporting company, has applied for what would be its fifth patent even as laboratory results indicate its revolutionary Hemp You Can Feel™ brand technology has exceeded expectations when it comes to infusing beverages, powders and liquid concentrates to such a degree that all hemp extracts and major cannabinoids are undetectable.

“We believe the uses for this advanced infusion technology are many, especially as a replacement for alcohol in various beverages,” MCTC Holdings CEO Arman Tabatabaei stated in a news release (

The Hemp You Can Feel innovation was introduced last month as a beverage industry solution for delivering relaxation to consumers without the negative health effects associated with alcohol consumption. The brand’s technology is based on an all-natural manufacturing process that doesn’t depend on any chemical surfactants, stabilizers or additives.

MCTC Holdings has been experimenting with cannabis-based polymeric solid nanoparticles and nanofibers, and while the company’s latest step forward involves non-nanoparticle technologies, they do nonetheless demonstrate chemical property levels many magnitudes lower than those typically seen in the marketplace.

The food and medical industries have long used nanoparticles to turn extremely small substances into rapid delivery mechanisms that can bypass the digestive system and go straight for the bloodstream, and the science is ripe with potential for cannabis applications. MCTC’s technology makes it possible to use very small amounts of extracts to achieve similar or superior results compared to other infusion methods.

MCTC plans to use the technology in products it expects to launch during the coming months as well as using it for the basis of a licensing strategy that will allow other companies to build branding from it on a “white label” manufacturing base at MCTC’s licensed Los Angeles facility.

The company announced December 12 it was filing for a new patent subsequent to the positive test results.

“We have produced some spectacular results and test data on this new technology and we are in discussions with several companies that are planning product introductions based on Hemp You Can Feel technology,” Tabatabaei stated ( “This marks our 5th patent with several more expected over the short term.”

Tabatabaei stated the next step for the company will be to create microparticle and nanoparticle forms of Hemp You Can Feel, and that development work has already begun toward that end. The company is also in the process of developing nanoparticle creation protocols for the cannabinol (CBN) extract and tetrahydrocannabivarin (THC-V) compound.

CBN is found only in small amounts and mostly results from oxidation of the other cannabinoids in cannabis, making it difficult to obtain and expensive as a result. An effective, minuscule-amount-tapping technology could make its use more cost-effective. THC-V is similar to tetrahyrdrocannabinol in molecular structure but has different outcomes, such as appetite suppression and bone-growth promotion (

“We think these new microparticle and nanoparticle technologies could prove very useful for advanced food and beverage infusion,” Tabatabaei stated. “We believe this additional area of research is especially topical considering the recent warnings put forth by the U.S. Food and Drug Administration concerning the use of CBD in foods and beverages.”

On November 25, the FDA announced a warning to more than a dozen companies for illegally selling products containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act, including marketing CBD products to treat diseases or for other therapeutic uses for humans or for animals.

Under the FD&C Act, a product qualifies as a drug if it claims to treat a disease or to have some other therapeutic or medical use, and is intended to affect the structure or function of the human or animal body other than for simple alimentary purposes. No CBD-based “drug” has been approved on a federal basis except for one company’s prescription to treat rare, severe forms of epilepsy in humans, so other CBD products marketed on an interstate basis may be found in violation, according to the FDA’s news release (

For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to MCTC are available in the company’s newsroom at

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published:

Do you have a questions or are you interested in working with CNW? Ask Our Editor

Denver, Colorado
303.498.7722 Office

CBDWire is part of the InvestorBrandNetwork.


Select A Month

CBDWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 303.498.7722